Cargando…

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

BACKGROUND: Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpose was to study the activity and cellular effects of this t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Djureinovic, Dijana, Weiss, Sarah A., Krykbaeva, Irina, Qu, Rihao, Vathiotis, Ioannis, Moutafi, Myrto, Zhang, Lin, Perdigoto, Ana L., Wei, Wei, Anderson, Gail, Damsky, William, Hurwitz, Michael, Johnson, Barbara, Schoenfeld, David, Mahajan, Amit, Hsu, Frank, Miller-Jensen, Kathryn, Kluger, Yuval, Sznol, Mario, Kaech, Susan M., Bosenberg, Marcus, Jilaveanu, Lucia B., Kluger, Harriet M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644655/ https://www.ncbi.nlm.nih.gov/pubmed/37964379 http://dx.doi.org/10.1186/s12943-023-01884-x

Ejemplares similares

A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma
por: Schoenfeld, David, et al.
Publicado: (2023)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma
por: Su, David, et al.
Publicado: (2023)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
por: Damsky, William, et al.
Publicado: (2019)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure
por: Qu, Rihao, et al.
Publicado: (2022)

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma
por: Oria, Victor O., et al.
Publicado: (2022)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

Anti-inflammatory treatments for stroke: from bench to bedside
por: Drieu, Antoine, et al.
Publicado: (2018)

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
por: Oria, Victor, et al.
Publicado: (2020)

Anti-PD-1 Therapy-Associated Perforating Colitis
por: Celli, Romulo, et al.
Publicado: (2018)

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
por: Aziz, Saadia A, et al.
Publicado: (2013)

Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
por: Jessel, Shlomit, et al.
Publicado: (2022)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

The presence of anti–SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
por: Ligtenberg, Katherine Given, et al.
Publicado: (2020)

Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside
por: Chung, Sungjin, et al.
Publicado: (2021)

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
por: Yang, Liyan, et al.
Publicado: (2023)

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
por: Jilaveanu, L.B., et al.
Publicado: (2014)

Characterizing disease states from topological properties of transcriptional regulatory networks
por: Tuck, David P, et al.
Publicado: (2006)

SIMVI reveals intrinsic and spatial-induced states in spatial omics data
por: Dong, Mingze, et al.
Publicado: (2023)

Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
por: Levi, Mattan, et al.
Publicado: (2020)

Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
por: Shamshiripour, Parisa, et al.
Publicado: (2022)

Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review
por: Heng, Jacob S, et al.
Publicado: (2022)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng
por: Aizenbud, Lilach, et al.
Publicado: (2023)

Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
por: Zyla, Joanna, et al.
Publicado: (2023)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Success is not necessarily automatic
por: Selkirk, Alastair B.
Publicado: (1998)

Why Does Hyperuricemia Not Necessarily Induce Gout?
por: Zhang, Wei-Zheng
Publicado: (2021)

Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic
por: Kluger, Dan M., et al.
Publicado: (2020)

Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

Unraveling condition specific gene transcriptional regulatory networks in Saccharomyces cerevisiae
por: Kim, Hyunsoo, et al.
Publicado: (2006)

VDA, a Method of Choosing a Better Algorithm with Fewer Validations
por: Strino, Francesco, et al.
Publicado: (2011)

Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
por: Moutafi, Myrto K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4cd40vf3e87uo1l6apiuu7p5kn